1315 Capital
No summary available yet.
1315 Capital is a solid mid-tier fund that actually knows their sectors, especially healthcare where Nikhil Krishnan brings real expertise and network. They're not going to lead your Series C, but they can be genuinely helpful at Series A/B with operational support and introductions. Chris Sugden has been-there-done-that credibility as a former operator. The fund is still relatively new (launched 2020) so track record is limited, but early portfolio companies speak positively about their involvement. They won't give you the brand name cachet of top-tier funds, but they also won't ghost you post-investment.
- —Best for: Series A/B healthcare and fintech companies wanting hands-on operational help
- —Known for: Deep healthcare expertise through Nikhil Krishnan and solid operator backgrounds
- —Watch out for: Newer fund with limited exit track record and smaller network than established names
1315 Capital focuses on Series A and B investments in technology companies across healthcare, fintech, and enterprise software. They position themselves as founder-friendly capital with a focus on helping companies scale from initial product-market fit to growth stage.
Series A/B focused with $100M+ fund targeting healthcare tech, fintech, and B2B SaaS companies primarily in the Northeast corridor. Typical check sizes $3-10M.
Former CEO and operator with exits including selling his company to IBM. Known for hands-on operational support and strong network in healthcare and enterprise software.
Healthcare-focused investor and prolific healthcare newsletter writer (Out-of-Pocket). Well-connected in healthcare tech circles and brings deep sector expertise.
Have a specific question about 1315 Capital?
Ask Bernie →